Clinicopathological Characteristics of Hyperdiploidy with High-Risk Cytogenetics in Multiple Myeloma.
10.3343/alm.2018.38.2.160
- Author:
Naery YANG
1
;
Yeung Chul MUN
;
Chu Myong SEONG
;
Hee Jin HUH
;
Jungwon HUH
Author Information
1. Department of Laboratory Medicine, College of Medicine, Ewha Womans University, Seoul, Korea. JungWonH@ewha.ac.kr
- Publication Type:Brief Communication
- Keywords:
Hyperdiploidy;
Multiple myeloma;
Cytogenetics;
High risk
- MeSH:
beta 2-Microglobulin;
Bone Marrow;
Cytogenetics*;
Fluorescence;
Humans;
In Situ Hybridization;
Interphase;
Metaphase;
Multiple Myeloma*;
Trisomy
- From:Annals of Laboratory Medicine
2018;38(2):160-164
- CountryRepublic of Korea
- Language:English
-
Abstract:
In multiple myeloma (MM), hyperdiploidy (HD) is known to impart longer overall survival. However, it is unclear whether coexistent HD ameliorates the adverse effects of known high-risk cytogenetics in MM patients. To address this issue, we investigated the clinicopathological characteristics of HD with high-risk cytogenetics in MM. Ninety-seven patients with MM were included in the study. For metaphase cytogenetics (MC), unstimulated cells from bone marrow aspirates were cultured for either 24 or 48 hours. To detect HD by interphase fluorescence in situ hybridization (iFISH), we assessed trisomies of chromosomes 5, 7, 9, 11, 15, and 17. Of the 97 MM patients, 40 showed HD. The frequency of co-occurrence of HD and high-risk cytogenetics was 14% (14/97). When the clinicopathological characteristics were compared between the two groups of HD with high-risk cytogenetics vs. non-HD (NHD) with high-risk cytogenetics, the level of beta 2 microglobulin and stage distribution significantly differed (P=0.020, P=0.032, respectively). This study shows that some of the clinicopathological characteristics of MM patients with high-risk cytogenetics differ according to HD or NHD status.
